Clinical trial

A Study to Evaluate the Safety and Tolerability of ALN-APP in Patients With EOAD

NCT05231785

StatusRECRUITING
Study typeINTERVENTIONAL
Start date2022-02-04
PhasePHASE1

Study timeline

Study start (actual)2022-02-04Date precision: day
Registry last updated2026-09-14
Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

What this registered study describes

A Study to Evaluate the Safety and Tolerability of ALN-APP in Patients With EOAD is a interventional study listed under registry identifier NCT05231785. Its last published status is RECRUITING. Registry status does not establish that enrollment is currently open at every study site.

The published record lists 1 condition label(s), 2 intervention label(s), and 1 sponsor/collaborator entry or entries. The structured information below allows these links to be examined individually; intervention registration is not an efficacy claim.

Source: the original ClinicalTrials.gov study record. Always check the protocol, eligibility, dates, results (when posted), and contacts at the original source.

How to interpret this record

CureCurrent links normalized diseases, medicines, registry study labels, sponsors and research sites. A link is not the same as a finding of clinical effectiveness. Our research guides explain how to compare studies, decode RxNorm identities, and avoid over-interpreting site and trial counts. See the published database coverage for mapping completeness.

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.